Trastuzumab Deruxtecan Receives Expedited Review in Japan for Gastric Cancer

Japanese regulators have granted a Sakigake designation to trastuzumab deruxtecan (DS-8201), for the treatment of patients with HER2-positive gastric cancer that is refractory to trastuzumab (Herceptin).

Source

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply